[{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Benztropine","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Benztropine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAPS 2024
                          Not Confirmed
                          AAPS 2024
                          Not Confirmed

                          Details : Benztropine is an anticholinergic medication approved as an adjunct for treatment of all forms of parkinsonism, including drug-induced parkinsonism that causes movement problems similar to those seen in Parkinson's disease, such as tremors, slow movement...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 19, 2022

                          Lead Product(s) : Benztropine

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank